Assessing GoodRx Holdings (GDRX) Valuation After Employer Direct Launch And Post Earnings Analyst Shifts

Simply Wall St.02-28 09:36

GoodRx Holdings (GDRX) is back in focus after launching its Employer Direct platform to help companies reduce high-impact brand drug costs, alongside 2025 earnings, fresh 2026 guidance, and a cluster ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614990899?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice1-main-header/1585186828574","is_english":true,"pubTime":"2026-02-28 09:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614990899","market":"us","top_or_hot":-1,"title":"Assessing GoodRx Holdings (GDRX) Valuation After Employer Direct Launch And Post Earnings Analyst Shifts","media":"Simply Wall St.","content":"<div>\n<p>GoodRx Holdings (GDRX) is back in focus after launching its Employer Direct platform to help companies reduce high-impact brand drug costs, alongside 2025 earnings, fresh 2026 guidance, and a cluster ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-gdrx/goodrx-holdings/news/assessing-goodrx-holdings-gdrx-valuation-after-employer-dire\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing GoodRx Holdings (GDRX) Valuation After Employer Direct Launch And Post Earnings Analyst Shifts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing GoodRx Holdings (GDRX) Valuation After Employer Direct Launch And Post Earnings Analyst Shifts\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-28 09:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-gdrx/goodrx-holdings/news/assessing-goodrx-holdings-gdrx-valuation-after-employer-dire><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>GoodRx Holdings (GDRX) is back in focus after launching its Employer Direct platform to help companies reduce high-impact brand drug costs, alongside 2025 earnings, fresh 2026 guidance, and a cluster ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-gdrx/goodrx-holdings/news/assessing-goodrx-holdings-gdrx-valuation-after-employer-dire\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GDRX","symbol_name":"GoodRx Holdings, Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gdrx/goodrx-holdings/news/assessing-goodrx-holdings-gdrx-valuation-after-employer-dire","article_id":"2614990899","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice1-main-header/1585186828574"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gdrx/goodrx-holdings/news/assessing-goodrx-holdings-gdrx-valuation-after-employer-dire","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2614990899","pubTimestamp":1772242577,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"GoodRx Holdings (GDRX) is back in focus after launching its Employer Direct platform to help companies reduce high-impact brand drug costs, alongside 2025 earnings, fresh 2026 guidance, and a cluster of analyst rating changes.\nSee our latest analysis for GoodRx Holdings.\nGoodRx’s recent earnings update, 2026 revenue guidance and the Employer Direct launch have been followed by a sharp reset in sentiment, with a 7 day share price return of 24.29% decline and a 1 year total shareholder return...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"GDRX":"GoodRx Holdings, Inc.","POST":"Post Holdings"},"translate_title":"在雇主直接推出和盈利分析师变动后评估GoodRx Holdings(GDRX)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"POST":1.5,"GDRX":1.5},"content_text":"GoodRx Holdings (GDRX) is back in focus after launching its Employer Direct platform to help companies reduce high-impact brand drug costs, alongside 2025 earnings, fresh 2026 guidance, and a cluster of analyst rating changes. See our latest analysis for GoodRx Holdings. GoodRx’s recent earnings update, 2026 revenue guidance and the Employer Direct launch have been followed by a sharp reset in sentiment, with a 7 day share price return of 24.29% decline and a 1 year total shareholder return of 62.45% decline, signalling fading momentum. If this shift in sentiment has you rethinking where growth might come from, you may want to broaden your search and check out 19 top founder-led companies for fresh ideas beyond GoodRx. With the share price under pressure, a value score of 4, an intrinsic discount of about 77% and analysts’ targets far above the last close, you have to ask: is this a reset opportunity or is future growth already priced in? AdvertisementMost Popular Narrative: 59% Undervalued GoodRx’s most followed narrative pegs fair value at $4.56 per share, well above the last close of $1.87. This highlights the gap between the model and the market.  Substantial momentum in the company's pharma manufacturer solutions (32% YoY revenue growth, with management projecting 30%+ in 2025) reflects strong demand for direct-to-patient engagement, unlocking higher-margin revenue streams and providing meaningful upside to consolidated revenue and net margins.  Read the complete narrative. Want to see what sits behind that upside story, revenue assumptions, margin expansion and the profit multiple the narrative leans on, all pulled together into one valuation blueprint? Result: Fair Value of $4.56 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the story can change quickly if pharmacy and PBM partners pull back on programs or if new competitors and pricing rules undercut GoodRx’s role at the counter. Find out about the key risks to this GoodRx Holdings narrative. Another Angle on Valuation While the fair value narrative points to GoodRx trading at a 77.1% discount, the current P/E of 20.9x sits slightly above the fair ratio of 19.4x. It is, however, lower than both the global Healthcare Services average of 31.7x and the peer average of 44.3x. So is this a margin of safety or a value trap in disguise? See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:GDRX P/E Ratio as at Feb 2026Next Steps If the mixed tone so far has you undecided, this is the moment to review the numbers yourself and act promptly. You can see how others are weighing the potential upside by checking 3 key rewards. Looking for more investment ideas? If GoodRx has sharpened your thinking, do not stop here. Use focused stock lists to quickly spot other opportunities that might suit your approach.  Target stability first by checking companies on our 76 resilient stocks with low risk scores and see which names stand out for their resilience. Hunt for potential value by scanning screener containing 24 high quality undiscovered gems that pair solid fundamentals with lower market attention. Prioritise financial strength by using the solid balance sheet and fundamentals stocks screener (39 results) to find businesses with sturdier balance sheets backing their stories.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614990899","isCrawlerRequest":true}